<DOC>
	<DOCNO>NCT00616434</DOCNO>
	<brief_summary>The primary objective study evaluate clinical activity interferon beta-1a participant moderate severe ulcerative colitis ( UC ) . Secondary objective study determine ( ) safety tolerability interferon beta-1a participant moderate severe UC , ( ii ) percentage participant , decrease Simple Clinical Colitis Activity Index ( SCCAI ) score ≥3 point Week 8 .</brief_summary>
	<brief_title>A Phase 2 Study Interferon Beta-1a ( Avonex® ) Ulcerative Colitis</brief_title>
	<detailed_description />
	<mesh_term>Ulcer</mesh_term>
	<mesh_term>Colitis , Ulcerative</mesh_term>
	<mesh_term>Colitis</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Interferon-beta</mesh_term>
	<mesh_term>Interferon beta-1a</mesh_term>
	<criteria>Key Established diagnosis ulcerative colitis ( UC ) ≥6 month 20 cm active disease Screening endoscopy Must active UC Mayo Score/Disease Activity Index ( DAI ) 6 13 point moderate severe disease endoscopy ( Mayo endoscopic score least 2 ) despite prior concomitant treatment Colonoscopy within past 5 year extent disease exclude polyp For subject UC 10 year , colonoscopy appropriate biopsy within 1 year prior Screening exclude dysplasia neoplasia . Must willing able practice effective birth control study 1 month last dose study treatment . Key Diagnosis indeterminate colitis Crohn 's disease Need imminent surgery Diagnosis primary sclerosing cholangitis toxic megacolon Hemoglobin ≤9 g/dL White blood cell count &lt; 3500 cells/mm^3 Lymphocyte count &lt; 1000 cells/µL Platelet count &lt; 100,000 cells/µL Female subject pregnant wish become pregnant study , lactate Known symptomatic colonic stricture Stool culture positive enteric infection History malignant disease History major abdominal surgery ( e.g. , gastrectomy ) within past 5 year History small bowel colonic obstruction resection History drug alcohol abuse ( define Investigator ) within 2 year prior Screening Use antidiarrheal agent screen period Previous participation study Previous treatment interferon beta interferon product NOTE : Other protocol define Inclusion/Exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>July 2014</verification_date>
</DOC>